Pacira BioSciences, Inc. (NASDAQ:PCRX) Insider Sells $16,173.60 in Stock

Pacira BioSciences, Inc. (NASDAQ:PCRX) insider Jonathan Slonin sold 879 shares of Pacira BioSciences stock in a transaction on Monday, January 6th. The shares were sold at an average price of $18.40, for a total value of $16,173.60. Following the transaction, the insider now owns 93,444 shares in the company, valued at approximately $1,719,369.60. This trade represents a 0.93 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Pacira BioSciences Stock Down 0.5 %

Shares of Pacira BioSciences stock opened at $18.58 on Thursday. Pacira BioSciences, Inc. has a 1 year low of $11.16 and a 1 year high of $35.81. The company has a market cap of $857.89 million, a P/E ratio of -9.15 and a beta of 0.76. The company has a current ratio of 2.25, a quick ratio of 1.89 and a debt-to-equity ratio of 0.51. The stock has a 50-day moving average price of $18.15 and a 200 day moving average price of $17.79.

Wall Street Analyst Weigh In

Several equities research analysts have commented on PCRX shares. Royal Bank of Canada boosted their price target on shares of Pacira BioSciences from $15.00 to $16.00 and gave the stock a “sector perform” rating in a research report on Thursday, November 7th. HC Wainwright reissued a “buy” rating and set a $39.00 target price on shares of Pacira BioSciences in a research note on Wednesday, December 4th. Jefferies Financial Group lifted their price target on shares of Pacira BioSciences from $15.00 to $18.00 and gave the stock a “buy” rating in a research report on Tuesday, September 24th. Needham & Company LLC reiterated a “buy” rating and set a $22.00 price objective on shares of Pacira BioSciences in a research report on Friday, November 8th. Finally, Barclays decreased their target price on Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating on the stock in a report on Tuesday, November 12th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $23.50.

Institutional Trading of Pacira BioSciences

A number of hedge funds have recently made changes to their positions in the stock. Virtus Investment Advisers Inc. purchased a new position in Pacira BioSciences during the third quarter valued at approximately $98,000. State Street Corp boosted its stake in shares of Pacira BioSciences by 5.8% during the 3rd quarter. State Street Corp now owns 2,014,012 shares of the company’s stock valued at $30,311,000 after buying an additional 110,162 shares during the period. Centiva Capital LP purchased a new position in shares of Pacira BioSciences during the 3rd quarter valued at $398,000. PDT Partners LLC purchased a new stake in shares of Pacira BioSciences during the third quarter worth $3,469,000. Finally, Verition Fund Management LLC purchased a new stake in shares of Pacira BioSciences during the third quarter worth $493,000. 99.73% of the stock is owned by hedge funds and other institutional investors.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.